4OT5 image
Deposition Date 2014-02-13
Release Date 2014-05-14
Last Version Date 2023-09-20
Entry Detail
PDB ID:
4OT5
Title:
Crystal structure of BTK kinase domain complexed with 4-tert-Butyl-N-(3-{8-[4-(4-methyl-piperazine-1-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzamide
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.55 Å
R-Value Free:
0.19
R-Value Work:
0.14
R-Value Observed:
0.14
Space Group:
P 21 21 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Tyrosine-protein kinase BTK
Gene (Uniprot):BTK
Mutations:M489A, R492A, E624A, K625A
Chain IDs:A
Chain Length:283
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis.
J.Med.Chem. 58 512 516 (2015)
PMID: 24712864 DOI: 10.1021/jm500305p

Abstact

Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis. Highlights include the introduction of a benzyl alcohol group and a fluorine substitution, each of which resulted in over 10-fold increase in activity. Concurrent optimization of drug-like properties led to compound 1 (RN486) (J. Pharmacol. Exp. Ther. 2012 , 341 , 90), which was selected for advanced preclinical characterization based on its favorable properties.

Legend

Protein

Chemical

Disease

Primary Citation of related structures